Anaphylactic shock: are we doing enough and with the right timing and order?

Open access

Abstract

Anaphylactic shock became, unfortunately, a common presence in Romanian mass-media, due to some fatal cases in the last months. The coincidence that in December 2014 the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy Asthma and Immunology released Practice parameters offers a good opportunity to renew for all practitioners what is now considered the “golden standard” of good practice.

Epinephrine must be considered the cornerstone and the most urgent measure to be applied in these cases, immediately after the diagnosis. A very important notice is to forget the administration of antihistamines or corticosteroids as first line therapy instead of epinephrine. Proper positioning of the subjects and quick fluid replacement (1-2 l of normal saline in a few minutes) are also mandatory.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. KEMP SF LOCKEY RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol. Sep. 2002; 110(3):341-8.

  • 2. ALRASBI M SHEIKH A. Comparison of international guidelines for the emergency medical management of anaphylaxis. Allergy. Aug. 2007; 62(8):838-41.

  • 3. LAIDMAN J. Anaphylaxis requires prompt epinephrine shot. Medscape Medical News [serial online]. December 3 2014; Accessed December 6 2014. Available at http://www.medscape.com/viewarticle/835786.

  • 4. CAMPBELL RL LI JT NICKLAS RA SADOSTY AT. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol. Dec. 2014; 113(6):599-608.

  • 5. WORKING GROUP OF THE RESUSCITATION COUNCIL (UK). Emergency treatment of anaphylactic reactions: guidelines for healthcare providers. 2008.

  • 6. ELLIS AK DAY JH. Diagnosis and management of anaphylaxis. CMAJ 2003; 169:307-11.

  • 7. AMERICAN HEART ASSOCIATION. GUIDELINES FOR CARDIOPULMONARY RESUSCITATION AND EMERGENCY CARDIOVASCULAR CARE: PART 10.6: Anaphylaxis. Circulation 2005; 112:143-5.

  • 8. SIMONS FE. Anaphylaxis pathogenesis and treatment. Allergy. Jul. 2011; 66 Suppl 95:31-4.

  • 9. PUMPHREY RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol. Aug. 2003; 112(2):451-2.

  • 10. ACUTE CARE UNDERGRADUATE TEACHING (ACUTE) INITIATIVE. A joint publication from the Resuscitation Council (UK) and Intercollegiate Board for Training in Intensive Care Medicine. 2005.

  • 11. O’DRISCOLL BR HOWARD LS DAVISON AG. BTS guideline for emergency oxygen use in adult patients. Thorax 2008; 63 (Suppl 6):vi1-68.

  • 12. NURMATOV U WORTH A SHEIKH A. Anaphylaxis management plans for the acute and long-term management of anaphylaxis: a systematic review. J Allergy Clin Immunol. Aug. 2008; 122(2):353-61 361.e1-3.

  • 13. LIEBERMAN P. Use of epinephrine in the treatment of anaphylaxis. Curr Opin Allergy Clin Immunol. Aug. 2003; 3(4):313-8.

  • 14. KEMP SF LOCKEY RF SIMONS FE. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy. Aug. 2008; 63(8):1061-70.

  • 15. SHEIKH A SHEHATA YA BROWN SGA SIMONS FER. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. Cochrane Data Syst Rev 2008; 4:CD006312 doi:

  • 16. BRAGANZA SC ACWORTH JP MCKINNON DR PEAKE JE BROWN AF. Paediatric emergency department anaphylaxis: different patterns from adults. Arch Dis Child. Feb. 2006; 91(2):159-63.

  • 17. YONG P. F. K. BIRNS J. IBRAHIM M. A. A. Anaphylactic shock: the great mimic. South Med. J. 2007; 100 (3): 295-297.

  • 18. HAUSMANN O SCHNYDER B PICHLER WJ. Drug hypersensitivity reactions involving skin. Handb Exp Pharmacol. 2010; 196:29-55

  • 19. FRIEDMANN P. S. ARDERN-JONES M. Patch testing in drug Allergy. Curr. Opin. Allergy Clin. Immunol. 2010; 10 (4): 291.

  • 20. SIMONS FE ARDUSSO LR BILÒ MB EL-GAMAL YM LEDFORD DK RING J et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. Mar. 2011; 127(3):587-93.e1-22.

  • 21. LIEBERMAN P NICKLAS RA OPPENHEIMER J et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. Sep. 2010; 126(3):477-80.e1-42.

  • 22. JOHANSSON SG BIEBER T DAHL R FRIEDMANN PS LANIER BQ LOCKEY RF et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization October 2003. J Allergy Clin Immunol. May 2004; 113(5):832-6.

  • 23. KEMP SF LOCKEY RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002; 110:341-348

  • 24. AKIN C. Anaphylaxis and mast cell disease: what is the risk? Curr Allergy Asthma Rep. Jan. 2010; 10(1):34-8.

  • 25. DYKEWICZ MS. Anaphylaxis and inflammation. Clin Allergy Immunol 2002; 16:401-409.

  • 26. KEMP SF. Current concepts in pathophysiology diagnosis and management of anaphylaxis. Immunol Allergy Clin North Am 2001; 21:611-634

  • 27. VADAS P GOLD M PERELMAN B et al. Platelet-activating factor PAF acetylhydrolase and severe anaphylaxis. N Engl J Med. Jan. 3 2008; 358(1):28-35.

  • 28. NEUGUT AI GHATAK AT MILLER RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med 2001; 161:15-21.

  • 29. YOCUM MW KHAN DA. Assessment of patients who have experienced anaphylaxis: a 3-year survey. Mayo Clin Proc 1994; 69:16-23.

  • 30. DECKER WW CAMPBELL RL MANIVANNAN V et al. The etiology and incidence of anaphylaxis in Rochester Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol. Dec. 2008; 122(6):1161-5.

  • 31. LIEBERMAN P. Epidemiology of anaphylaxis. Curr Opin Allergy Clin Immunol. Aug. 2008; 8(4):316-20.

  • 32. GREENBERGER PA. Idiopathic anaphylaxis. Immunol Allergy Clin North Am. May 2007; 27 (2):273-93 vii-viii.

  • 33. WANG J SAMPSON HA. Food anaphylaxis. Clin Exp Allergy. May 2007; 37(5):651-60.

  • 34. HOURIHANE JO'B KILBURN SA NORDLEE JA HEFLE SL TAYLOR SL WARNER JO. An evaluation of the sensitivity of subjects with peanut allergy to very low doses of peanut protein: a randomized double-blind placebo-controlled food challenge study. J Allergy Clin Immunol. Nov. 1997; 100(5):596-600.

  • 35. BOYCE JA ASSA'AD A BURKS AW JONES SM SAMPSON HA WOOD RA et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. Dec. 2010; 126(6 Suppl):S1-58.

  • 36. GOLDEN DB MOFFITT J NICKLAS RA FREEMAN T GRAFT DF REISMAN RE et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol. Apr. 2011; 127(4):852-4.e1-23

  • 37. RUEFF F PRZYBILLA B BILO MB et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. Nov. 2009; 124(5):1047-54.

  • 38. TORRES MJ BLANCA M FERNANDEZ J et alENDA; EAACI Interest Group on Drug Hypersensitivity. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003; 58:961-972.

  • 39. JOHNSON K. Antibiotics common cause of perioperative anaphylaxis. Medscape Medical News [serial online]. November 22 2013; Accessed December 3 2013. Available at http://www.medscape.com/viewarticle/814903.

  • 40. DAULAT S SOLENSKY R EARL HS CASEY W GRUCHALLA RS. Safety of cephalosporin administration to patients with histories of penicillin allergy. J Allergy Clin Immunol. Jun. 2004; 113(6):1220-2.

  • 41. PICHICHERO ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics. Apr. 2005; 115(4):1048-57.

  • 42. DEMOLY P ROMANO A BOTELHO C et al. Determining the negative predictive value of provocation tests with beta-lactams. Allergy. 2010; 65:327-332.

  • 43. OWNBY DR. A history of latex allergy. J Allergy Clin Immunol 2002; 110:S27-S32.

  • 44. BAUER X. Epidemiology of latex sensitization. J Allergy Clin Immunol 2003; 111:652.

  • 45. MERTES PM MALINOVSKY JM JOUFFROY L et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011; 21(6):442-53.

  • 46. AMIN HS LISS GM BERNSTEIN DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. Jan. 2006; 117(1):169-75.

  • 47. 47.BERNSTEIN DI WANNER M BORISH L LISS GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. Jun. 2004; 113(6):1129-36.

  • 48. LOCKEY RF BENEDICT LM TURKELTAUB PC BUKANTZ SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. Apr. 1987; 79(4):660-77.

  • 49. LEE S HESS EP NESTLER DM BELLAMKONDA ATHMARAM VR BELLOLIO MF DECKER WW et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol. Apr. 2013; 131(4):1103-8.

  • 50. BOGGS W. Anaphylaxis worse with antihypertensive medication. Medscape Medical News. March 21 2013. Available at http://www.medscape.com/viewarticle/781274.

  • 51. KATAYAMA H YAMAGUCHI K KOZUKA T TAKASHIMA T SEEZ P MATSUURA K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media.Radiology. Jun. 1990; 175(3):621-8.

  • 52. GREENBERGER PA PATTERSON R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol. Apr. 1991; 87(4):867-72.

  • 53. SLATER JE RAPHAEL G CUTLER GB JR LORIAUX DL MEGGS WJ KALINER M. Recurrent anaphylaxis in menstruating women: treatment with a luteinizing hormone-releasing hormone agonist – a preliminary report. Obstet Gynecol. Oct. 1987; 70(4):542-6.

  • 54. KEMP SF. The post-anaphylaxis dilemma: how long is long enough to observe a patient after resolution of symptoms? Curr Allergy Asthma Rep. Mar. 2008; 8(1):45-8.

  • 55. POSADAS SJ PICHLER WJ. Delayed drug hypersensitivity reactions – new concepts. Clin Exp Allergy. 2007; 37:989-999.

  • 56. LIEBERMAN PL. Specific and idiopathic anaphylaxis: pathophysiology and treatment. In: Bierman CW Pearlman DS Shapiro GG et al. eds. Allergy Asthma and Immunology From Infancy to Adulthood. Third edition. Philadelphia WB Saunders 1996 pp. 297-319.

  • 57. SIMONS FE SAMPSON HA. Anaphylaxis epidemic: fact or fiction? J Allergy Clin Immunol. Dec. 2008; 122(6):1166-8.

  • 58. MONERET-VAUTRIN DA MORISSET M FLABBEE J BEAUDOUIN E KANNY G. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy. Apr. 2005; 60(4):443-51.

  • 59. DEMUTH KA FITZPATRICK AM. Epinephrine autoinjector availability among children with food allergy. Allergy Asthma Proc. Jul. 2011; 32(4):295-300.

  • 60. JOSE R CLESHAM GJ. Survey of the use of epinephrine (adrenaline) for anaphylaxis by junior hospital doctors. Postgrad Med J 2007; 83:610-1.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 692 452 45
PDF Downloads 583 428 50